Skip to main content

Drug Interactions between levoketoconazole and Opdivo Qvantig

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nivolumab levoketoconazole

Applies to: Opdivo Qvantig (hyaluronidase / nivolumab) and levoketoconazole

MONITOR: Concomitant use of immune checkpoint inhibitors (ICIs) such as anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 monoclonal antibodies and/or inhibitors of programmed cell death-1 (PD-1) or programmed death ligand-1 (PD-L1) with ketoconazole (and possibly with its enantiomer, levoketoconazole) may potentiate the risk of liver injury. The mechanism of this interaction is unknown. In one case series, 2 consecutive patients with different types of metastatic cancer (pituitary carcinoma and adrenal cortical carcinoma) received ketoconazole (800 mg/day) for Cushing syndrome and were later initiated on ICI therapy (nivolumab 3 mg/kg every 2 weeks for one and pembrolizumab 200 mg intravenous every 3 weeks for the other). Both patients exhibited normal liver function while on ketoconazole. However, after initiation of the ICI, the levels of each patient's alanine transaminase (ALT) and aspartate transaminase (AST) increased by 10- to 20-fold. Liver biopsies obtained for each patient were consistent with drug-induced hepatic injury. In both cases, the ICI and ketoconazole were discontinued, and treatment with methylprednisolone (62.5 mg/day) was initiated for hepatic injury. Liver function gradually improved and both patients recovered. Clinical data with levoketoconazole are not readily available.

MANAGEMENT: The risk of hepatic injury should be considered when immune checkpoint inhibitors (ICIs) are used in combination with ketoconazole and possibly levoketoconazole. Liver function tests should be monitored as clinically indicated and patients should be counseled to report any symptoms of liver damage such as fever, rash, right upper quadrant pain, dark urine, pale stools, and/or jaundice. Refer to the individual product labeling for the ICI in question as well as ketoconazole or levoketoconazole for more specific recommendations should signs or symptoms of hepatotoxicity occur.

References (2)
  1. Yang Y, Hecht JR, Liu ST, et al. (2020) "Caution advised using combination ketoconazole and PD-1 inhibitors." AACE Clin Case Rep, 6, e239-42
  2. Center for Drug Evaluation and Research (2025) Center for drug evaluation and research. Application number: 214133Orig1s000. Other review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214133Orig1s000OtherR.pdf

Drug and food interactions

Moderate

levoketoconazole food

Applies to: levoketoconazole

GENERALLY AVOID: Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury. Serious hepatotoxicity has been reported with levoketoconazole. Hepatotoxicity requiring liver transplantation has been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer. Some patients had no obvious risk factors for liver disease. In addition, use of alcohol or products containing alcohol during ketoconazole or levoketoconazole therapy may result in a disulfiram-like reaction in some patients. Symptoms of disulfiram-like reaction include flushing, rash, peripheral edema, nausea, and headache.

GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of ketoconazole or levoketoconazole. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Inhibition of hepatic CYP450 3A4 may also contribute. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

When administered to healthy volunteers with a high-fat meal (875 calories; 62% fat), levoketoconazole systemic exposure (AUC) increased by 30% while peak plasma concentration (Cmax) did not change and the time to reach Cmax (Tmax) was delayed from 2 to 4 hours, compared to fasted conditions.

MANAGEMENT: Levoketoconazole may be administered with or without food. Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy. Patients should preferably avoid or limit consumption of grapefruit, grapefruit juice, or any supplement containing grapefruit extract during ketoconazole or levoketoconazole therapy. Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.

References (4)
  1. (2019) "Product Information. Ketoconazole (ketoconazole)." Mylan Pharmaceuticals Inc
  2. (2022) "Product Information. Recorlev (levoketoconazole)." Xeris Pharmaceuticals Inc
  3. Auchus R, Pivonello R, Fleseriu M, et al. (2022) Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440
  4. (2021) "Product Information. Ketoconazole (ketoconazole)." Burel Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.